Table 2.

Most common AEs (more than 10%) attributed to pembrolizumab and vorinostat

Grade 1Grade 2Grade 3Grade 4n (%)
Hypertension 14 26 (81) 
Fatigue 18 22 (69) 
Nausea 20 22 (69) 
Hyponatremia 21 21 (66) 
Diarrhea 14 16 (50) 
Abdominal pain 13 14 (44) 
Platelet count decreased 12 14 (44) 
Anemia 11 13 (41) 
White blood cell decreased 13 (41) 
Vomiting 10 12 (38) 
Neutrophil count decreased 12 (38) 
Hypokalemia 10 11 (34) 
Rash maculopapular 10 10 (31) 
Hypophosphatemia 10 (31) 
Weight loss 10 (31) 
Anorexia 9 (28) 
Pruritus 8 (25) 
Headache 8 (25) 
Creatinine increased 8 (25) 
Aspartate aminotransferase increased 7 (22) 
Myalgia 7 (22) 
Dyspepsia 6 (19) 
Constipation 6 (19) 
Arthralgia 6 (19) 
Alanine aminotransferase increased 6 (19) 
Sinus bradycardia 5 (16) 
Alkaline phosphatase increased 5 (16) 
Atrioventricular block first degree 4 (13) 
Gastroesophageal reflux disease 4 (13) 
Lymphocyte count decreased 4 (13) 
Back pain 4 (13) 
Hypothyroidism 4 (13) 
Alopecia 4 (13) 
Grade 1Grade 2Grade 3Grade 4n (%)
Hypertension 14 26 (81) 
Fatigue 18 22 (69) 
Nausea 20 22 (69) 
Hyponatremia 21 21 (66) 
Diarrhea 14 16 (50) 
Abdominal pain 13 14 (44) 
Platelet count decreased 12 14 (44) 
Anemia 11 13 (41) 
White blood cell decreased 13 (41) 
Vomiting 10 12 (38) 
Neutrophil count decreased 12 (38) 
Hypokalemia 10 11 (34) 
Rash maculopapular 10 10 (31) 
Hypophosphatemia 10 (31) 
Weight loss 10 (31) 
Anorexia 9 (28) 
Pruritus 8 (25) 
Headache 8 (25) 
Creatinine increased 8 (25) 
Aspartate aminotransferase increased 7 (22) 
Myalgia 7 (22) 
Dyspepsia 6 (19) 
Constipation 6 (19) 
Arthralgia 6 (19) 
Alanine aminotransferase increased 6 (19) 
Sinus bradycardia 5 (16) 
Alkaline phosphatase increased 5 (16) 
Atrioventricular block first degree 4 (13) 
Gastroesophageal reflux disease 4 (13) 
Lymphocyte count decreased 4 (13) 
Back pain 4 (13) 
Hypothyroidism 4 (13) 
Alopecia 4 (13) 
Close Modal

or Create an Account

Close Modal
Close Modal